These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 37548691)

  • 1. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
    Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
    Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
    Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J
    Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
    Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
    [No Abstract]   [Full Text] [Related]  

  • 4. Chest computed tomography improvement in patients with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: Early report.
    Bec R; Reynaud-Gaubert M; Arnaud F; Naud R; Dufeu N; Di Bisceglie M; Coiffard B; Gaubert JY; Bermudez J; Habert P
    Eur J Radiol; 2022 Sep; 154():110421. PubMed ID: 35772339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal Evaluation of Bronchial Changes in Cystic Fibrosis Patients Undergoing Elexacaftor/Tezacaftor/Ivacaftor Therapy Using Lung MRI With Ultrashort Echo-Times.
    David M; Benlala I; Bui S; Benkert T; Berger P; Laurent F; Macey J; Dournes G
    J Magn Reson Imaging; 2024 Jul; 60(1):116-124. PubMed ID: 37861357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two
    Stahl M; Dohna M; Graeber SY; Sommerburg O; Renz DM; Pallenberg ST; Voskrebenzev A; Schütz K; Hansen G; Doellinger F; Steinke E; Thee S; Röhmel J; Barth S; Rückes-Nilges C; Berges J; Hämmerling S; Wielpütz MO; Naehrlich L; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
    Eur Respir J; 2024 Sep; 64(3):. PubMed ID: 38901883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
    J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Function in Patients with Cystic Fibrosis before and during
    Heidenreich JF; Kuhl PJ; Grunz JP; Hendel R; Metz C; Weng AM; Benkert T; Hebestreit H; Bley TA; Köstler H; Veldhoen S
    Radiology; 2023 Jul; 308(1):e230084. PubMed ID: 37404154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.
    McNally P; Lester K; Stone G; Elnazir B; Williamson M; Cox D; Linnane B; Kirwan L; Rea D; O'Regan P; Semple T; Saunders C; Tiddens HAWM; McKone E; Davies JC;
    Am J Respir Crit Care Med; 2023 Nov; 208(9):917-929. PubMed ID: 37703083
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
    Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
    Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI).
    Yule A; Ng C; Recto A; Lockwood F; Dellschaft NS; Hoad CL; Zagoya C; Mainz JG; Major G; Barr HL; Gowland PA; Stewart I; Marciani L; Spiller RC; Smyth AR
    J Cyst Fibros; 2024 Sep; 23(5):984-990. PubMed ID: 39242338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
    Southern KW; Murphy J; Sinha IP; Nevitt SJ
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis.
    Wucherpfennig L; Triphan SMF; Wege S; Kauczor HU; Heussel CP; Schmitt N; Wuennemann F; Mayer VL; Sommerburg O; Mall MA; Eichinger M; Wielpütz MO
    J Cyst Fibros; 2022 Nov; 21(6):1053-1060. PubMed ID: 35400600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
    Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
    mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
    Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
    J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort: Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment.
    Nielsen BU; Olsen MF; Mabuza Mathiesen IH; Pressler T; Ritz C; Katzenstein TL; Olesen HV; Skov M; Jensen-Fangel S; Almdal TP; Faurholt-Jepsen D
    J Cyst Fibros; 2024 Jan; 23(1):103-108. PubMed ID: 37989700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
    Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
    J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
    Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
    Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.